Last reviewed · How we verify
Sertraline + Olanzapine
Sertraline inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, together providing antidepressant and antipsychotic effects.
Sertraline inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, together providing antidepressant and antipsychotic effects. Used for Major depressive disorder with psychotic features, Treatment-resistant depression.
At a glance
| Generic name | Sertraline + Olanzapine |
|---|---|
| Also known as | Zyprexa |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | SSRI + atypical antipsychotic combination |
| Target | Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. This combination targets both serotonergic and dopaminergic pathways to address mood and psychotic symptoms.
Approved indications
- Major depressive disorder with psychotic features
- Treatment-resistant depression
Common side effects
- Weight gain
- Sedation
- Nausea
- Sexual dysfunction
- Metabolic syndrome
- Akathisia
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions (NA)
- Detoxification From the Lipid Tract (PHASE4)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Mechanism of Mindfulness-Based Online Intervention in Enhancing Cognitive Flexibility (NA)
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- The Mechanism of Mindfulness Intervention to Alleviate Emotional Distress in Patients With Emotional Disorders (NA)
- Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sertraline + Olanzapine CI brief — competitive landscape report
- Sertraline + Olanzapine updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI